Cooperativity of the oncoprotein SKI and the mutated receptor tyrosine kinase FLT3ITD in acute myeloid leukemia patients with normal karyotype

被引：0
|
作者：
Frech, M. [1 ,2 ]
Mernberger, M. [3 ]
Nist, A. [4 ]
Sengelmann, M. [1 ,2 ]
Alkan, A. [1 ,2 ]
Kellermann, T. [1 ,2 ]
Steding, H. [1 ,2 ]
Stiewe, T. [3 ,4 ]
Neubauer, A. [1 ,2 ]
机构：
[1] Philipps Univ Marburg, Clin Hematol Oncol, Immunol, Marburg, Germany
[2] Philipps Univ Marburg, Ctr Tumor Biol & Immunol, Marburg, Germany
[3] Philipps Univ Marburg, Inst Mol Oncol, Marburg, Germany
[4] Philipps Univ Marburg, Genom Core Facil, Marburg, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V1077
引用
收藏
页码：310 / 310
页数：1
相关论文
共 50 条
  • [41] TET2, ANPM1 and FLT3-ITD Gene Mutations in Normal Karyotype Acute Myeloid Leukemia
    Sun, Aining
    Tian, Xiaopeng
    Yin, Jia
    Li, Weiyang
    Chen, Suning
    Wu Depei
    BLOOD, 2012, 120 (21)
  • [42] Synergistic effect of FMS-like tyrosine kinase-3 (FLT3) inhibitors combined with a CDK7 inhibitor in FLT3-ITD-mutated acute myeloid leukemia
    Koo, Bon-Kwan
    Choi, Eun-Ji
    Moon, Ju Hyun
    Kim, Ji Yun
    Park, Hyunkyung
    Park, Han-Seung
    Choi, Yunsuk
    Lee, Jung-Hee
    Lee, Kyoo-Hyung
    Choi, Eun Kyung
    Kim, Eunji
    Lee, Je-Hwan
    Hur, Eun-Hye
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [43] Negative Impact of FLT3-ITD Mutation in Elderly Acute Myeloid Leukemia Patients (Age ≥70) Is Karyotype Dependent
    Talati, Chetasi
    Kuykendall, Andrew
    Al Ali, Najla
    Kim, Jongphil
    Sehovic, Marina
    Zuckerman, Kenneth S.
    Sallman, David A.
    List, Alan F.
    Padron, Eric
    Komrokji, Rami S.
    Djulbegovic, Benjamin
    Extermann, Martine
    Lancet, Jeffrey E.
    Sweet, Kendra
    BLOOD, 2017, 130
  • [44] Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia
    K Reiter
    H Polzer
    C Krupka
    A Maiser
    B Vick
    M Rothenberg-Thurley
    K H Metzeler
    D Dörfel
    H R Salih
    G Jung
    E Nößner
    I Jeremias
    W Hiddemann
    H Leonhardt
    K Spiekermann
    M Subklewe
    P A Greif
    Leukemia, 2018, 32 : 313 - 322
  • [45] Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia
    Reiter, K.
    Polzer, H.
    Krupka, C.
    Maiser, A.
    Vick, B.
    Rothenberg-Thurley, M.
    Metzeler, K. H.
    Doerfel, D.
    Salih, H. R.
    Jung, G.
    Noessner, E.
    Jeremias, I.
    Hiddemann, W.
    Leonhardt, H.
    Spiekermann, K.
    Subklewe, M.
    Greif, P. A.
    LEUKEMIA, 2018, 32 (02) : 313 - 322
  • [46] Incidence and significance of FLT3-ITD and NPM1 mutations in patients with normal karyotype acute myeloid leukaemia
    Haslam, K.
    Chadwick, N.
    Kelly, J.
    Browne, P.
    Vandenberghe, E.
    Flynn, C.
    Conneally, E.
    Langabeer, S. E.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2010, 179 (04) : 507 - 510
  • [47] FLT3 AND FLT3-ITD GENE MUTATIONS AND PROGNOSIS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
    Chen, L. G.
    Pei, R. Z.
    Lu, Y.
    Zhang, P. S.
    Liu, X. H.
    Du, X. H.
    Chen, D.
    Cao, J. J.
    Li, S. Y.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2019, 33 (06): : 1855 - 1861
  • [48] Incidence and significance of FLT3-ITD and NPM1 mutations in patients with normal karyotype acute myeloid leukaemia
    K. Haslam
    N. Chadwick
    J. Kelly
    P. Browne
    E. Vandenberghe
    C. Flynn
    E. Conneally
    S. E. Langabeer
    Irish Journal of Medical Science, 2010, 179 : 507 - 510
  • [49] Dasatinib Inhibits FLT3/ITD and PTPN11mutated Acute Myeloid Leukemia Cells Overexpressing SRC Tyrosine Kinases
    Tavor, Sigal
    Shalit, Tali
    Ilani, Noa Chapal
    Moskovitz, Yoni
    Livnat, Nir
    Groner, Yoram
    Bar, Haim
    Plotnikov, Alexander
    Kaushansky, Nathali
    Shlush, Liran I.
    BLOOD, 2019, 134
  • [50] Quizartinib with decitabine and venetoclax (triplet) is highly active in patients with FLT3-ITD mutated acute myeloid leukemia (AML).
    Yilmaz, Musa
    Kantarjian, Hagop M.
    Muftuoglu, Muharrem
    Kadia, Tapan M.
    Konopleva, Marina
    Borthakur, Gautam
    Dinardo, Courtney Denton
    Pemmaraju, Naveen
    Short, Nicholas James
    Alvarado, Yesid
    Montalban-Bravo, Guillermo
    Jurisprudenica, Carissa
    Pike, Allison
    Ohanian, Maro
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Ruvolo, Vivian
    Ravandi, Farhad
    Andreeff, Michael
    Daver, Naval Guastad
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345